NASDAQ
10.04.26 | 21:59
6,630 US-Dollar
+50,17 % +2,215
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Fr | Jefferies raises Zentalis stock price target on ovarian cancer trial data | 2 | Investing.com | ||
| Fr | Guggenheim erhöht Kursziel für Zentalis-Aktie nach positiven Daten zu Krebsmedikament | 5 | Investing.com Deutsch | ||
| Fr | Guggenheim raises Zentalis stock price target on ovarian cancer drug data | 1 | Investing.com | ||
| Fr | H.C. Wainwright reiterates Zentalis stock rating on pivotal dose selection | 1 | Investing.com | ||
| Do | Zentalis legt 400-mg-Dosis für Studie zu Eierstockkrebs-Medikament fest | 8 | Investing.com Deutsch | ||
| Do | Zentalis selects 400mg dose for ovarian cancer drug trial | 1 | Investing.com | ||
| Do | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 27.03. | TD Cowen reiterates Zentalis Pharmaceuticals stock Buy rating | 4 | Investing.com | ||
| 27.03. | H.C. Wainwright reiterates Zentalis stock rating, $10 target | 2 | Investing.com | ||
| 27.03. | Oppenheimer reiterates Zentalis stock rating on ovarian cancer drug | 2 | Investing.com | ||
| 27.03. | Zentalis: Oppenheimer bestätigt "Outperform"-Rating für Aktie dank Krebsmedikament | 1 | Investing.com Deutsch | ||
| 26.03. | Zentalis Pharmaceuticals, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 26.03. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.03. | Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates | 117 | GlobeNewswire (Europe) | On track for DENALI Part 2a dose confirmation in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalOn track to initiate the ASPENOVA Phase... ► Artikel lesen | |
| 17.03. | Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| 17.03. | Wells Fargo assumes coverage on Zentalis stock with $5 target | 3 | Investing.com | ||
| 17.03. | Zentalis: Wells Fargo übernimmt Coverage mit "Equal Weight" und Kursziel von 5 US-Dollar | 2 | Investing.com Deutsch | ||
| 09.01. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 15.12.25 | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 43,330 | -0,30 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| VALNEVA | 2,668 | -1,11 % | Valneva mit Rekordsignal: Was große Adressen zum Wochenstart bereits wissen - Was erfahrene Anleger jetzt analysieren | ||
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| NUREXONE BIOLOGIC | 0,420 | +2,94 % | Megatrend Nanotechnologie und NurExone im Fokus einer neuen Wachstumsphase | ||
| IMMUNITYBIO | 6,140 | -1,13 % | IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results | ||
| CARDIFF ONCOLOGY | 1,409 | +4,91 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief... ► Artikel lesen | |
| ALDEYRA | 1,520 | 0,00 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,140 | -0,48 % | Jefferies reiterates Iovance Biotherapeutics stock rating at buy | ||
| GUARDANT HEALTH | 67,16 | 0,00 % | Wachstum bei Krebstests: Canaccord bestätigt Kaufempfehlung für Guardant Health | ||
| OCULAR THERAPEUTIX | 7,400 | -1,33 % | Johnson Fistel, PLLP: Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses | San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc. (NASDAQ: OCUL). The investigation... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,453 | +1,68 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| ESPERION | 1,869 | +0,75 % | Esperion Therapeutics, Inc.: Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) | - Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,154 | 0,00 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| MACROGENICS | 3,000 | -2,60 % | Weekly Buzz: MacroGenics Resumes LINNET; GSK Wins China Nod; FDA Okays Waters Corporation; Neurocrine Biosciences Snaps Up Soleno Therapeutics | THOUSAND OAKS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations... ► Artikel lesen | |
| OPGEN | 1,568 | 0,00 % | OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc. | CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC: OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in... ► Artikel lesen |
Das Unternehmen ZENTALIS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +2,215 (+50,17 %) liegt der Kurs bei 6,630 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENTALIS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.